000 | 04915cam a2200541Ii 4500 | ||
---|---|---|---|
001 | ocn948296971 | ||
003 | OCoLC | ||
005 | 20190719103232.0 | ||
006 | m o d | ||
007 | cr cnu|||unuuu | ||
008 | 160429s2016 enk ob 001 0 eng d | ||
040 |
_aN$T _beng _erda _epn _cN$T _dOPELS _dN$T _dYDXCP _dOCLCF _dYDX _dUPM _dU3W _dD6H _dAU@ _dWYU |
||
019 |
_a958084149 _a958392409 _a1066462332 |
||
020 |
_a9780323428668 _qelectronic bk. |
||
020 |
_a0323428665 _qelectronic bk. |
||
020 |
_z9780323428668 _qprint |
||
020 | _a9780323428897 | ||
020 | _a0323428894 | ||
035 |
_a(OCoLC)948296971 _z(OCoLC)958084149 _z(OCoLC)958392409 _z(OCoLC)1066462332 |
||
050 | 4 | _aTA418.9.N35 | |
072 | 7 |
_aTEC _x009000 _2bisacsh |
|
072 | 7 |
_aTEC _x035000 _2bisacsh |
|
082 | 0 | 4 |
_a620.1/15 _223 |
245 | 0 | 0 |
_aNanobiomaterials in drug delivery : _bapplications of nanobiomaterials / _cedited by Alexandru Mihai Grumezescu. |
264 | 1 |
_aKidlington, Oxford, UK : _bWilliam Andrew is an imprint of Elsevier, _c2016. |
|
300 | _a1 online resource | ||
336 |
_atext _btxt _2rdacontent |
||
337 |
_acomputer _bc _2rdamedia |
||
338 |
_aonline resource _bcr _2rdacarrier |
||
504 | _aIncludes bibliographical references and index. | ||
588 | 0 | _aOnline resource; title from PDF title page (ScienceDirect, viewed May 9, 2016). | |
505 | 0 | _aFront Cover; Nanobiomaterials in Drug Delivery; Copyright Page; Contents; List of contributors; Preface of the series; Preface; About the Series (Volumes I-XI); About Volume IX; 1 Nanobiomaterials in drug delivery; Abbreviations; 1.1 Introduction; 1.1.1 Parameters of Delivery of Nanoparticles into Biological Systems; 1.1.2 Intratumor Drug Release; 1.1.3 Biological Clearance; 1.1.4 Toxicity of Nanoparticles; 1.2 Preparation and Characterization of Nanomaterials; 1.2.1 Preparation; 1.2.2 Characterization; 1.2.2.1 Physicochemical characterization. | |
505 | 8 | _a1.3 Nanotechnology-Assisted Formulating of Poorly Water-Soluble Compounds1.4 Biodegradable Polymers Used in Controlled Drug Delivery; 1.5 Multifunctional Nanomaterials for Cancer Therapy; 1.5.1 Targeting; 1.5.2 Imaging; 1.5.3 Chemotherapy; 1.6 Chemical Conjugation of Nanomaterials; 1.6.1 pH-Sensitive Linkages Used for Bioconjugation of Nanomaterials; 1.6.2 Other Chemical Linkages Used for Bioconjugation of Nanomaterials; 1.7 Conclusions; Acknowledgments; References; 2 Dendrimers in drug delivery; 2.1 Introduction; 2.2 Mechanisms of Interaction Between Dendrimers and Drug Molecules. | |
505 | 8 | _a2.3 Dendrimers as Carriers of Various Types of Drugs2.3.1 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs); 2.3.2 Anticancer Drugs; 2.3.3 Other Drugs; 2.4 Routes of Administration of Drug-Dendrimers Complexes; 2.4.1 Dendrimers in Intravenous Drug Delivery; 2.4.2 Dendrimers in Oral Drug Delivery; 2.4.3 Dendrimers in Transdermal Drug Delivery; 2.4.4 Dendrimers in Ocular Drug Delivery; 2.4.5 Dendrimers in Pulmonary Drug Delivery; 2.5 Conclusions and Further Prognosis; Acknowledgments; References; 3 Lipid nanoparticles as non-viral vectors for siRNA delivery: concepts and applications. | |
505 | 8 | _a3.1 Introduction3.2 siRNA: Definition, Mechanism, and Applications; 3.3 Hurdles for siRNA Delivery; 3.4 Strategies to Overcome the Hurdles of siRNA Delivery; 3.4.1 Chemical Modifications in siRNA; 3.4.2 Physical Methods for siRNA Delivery; 3.4.3 Viral Carriers for siRNA Delivery; 3.4.4 Non-viral Carriers for siRNA Delivery; 3.5 Liposomes: The Influence of Charge and Lipid Composition for siRNA Delivery; 3.5.1 Cationic Lipid-Based siRNA Delivery Systems; 3.5.2 Neutral Lipid-Based siRNA Delivery Systems; 3.5.3 Anionic Lipid-Based siRNA Delivery Systems; 3.5.4 Stealth Liposomes. | |
505 | 8 | _a3.6 Targeted Delivery of siRNA-Loaded Liposomes3.7 Combined Therapy of siRNA-Loaded Liposomes and Conventional Small-Molecule Drugs; 3.8 siRNA-Loaded Liposomes Associated with Physical Methods; 3.9 siRNA-Loaded Liposomes: Clinical Studies; 3.10 Conclusions and Perspectives; References; 4 Nanobiomaterials: Novel nanoplatforms for protein and peptide delivery; 4.1 Introduction; 4.2 Proteins/Peptides as Therapeutics; 4.2.1 Group I-Protein Therapeutics with Enzymatic or Regulatory Activity; 4.2.2 Group II-Protein Therapeutics with Special Targeting Activity; 4.2.3 Group III-Proteinaceous Vaccines. | |
650 | 0 | _aNanostructured materials. | |
650 | 0 | _aNanomedicine. | |
650 | 0 | _aNanobiotechnology. | |
650 | 7 |
_aTECHNOLOGY & ENGINEERING / Engineering (General) _2bisacsh |
|
650 | 7 |
_aTECHNOLOGY & ENGINEERING / Reference _2bisacsh |
|
650 | 7 |
_aNanobiotechnology. _2fast _0(OCoLC)fst01894713 |
|
650 | 7 |
_aNanomedicine. _2fast _0(OCoLC)fst01744350 |
|
650 | 7 |
_aNanostructured materials. _2fast _0(OCoLC)fst01032630 |
|
655 | 4 | _aElectronic books. | |
700 | 1 |
_aGrumezescu, Alexandru Mihai, _eeditor. |
|
856 | 4 | 0 |
_3ScienceDirect _uhttp://www.sciencedirect.com/science/book/9780323428668 |
999 |
_c503921 _d503856 |